POSTER SESSION IV
Tuesday, March 23, 2010 — 1:00 PM - 4:30 PM
Exhibit Hall
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
BREAST PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
1
100% Concordance between IHC and FISH HER2 Testing Cannot Be Achieved Using N9831 Cohort
(267)
AE McCullough, B Chen, DW Hillman, KS Tenner, RB Jenkins, MM Reinholz, WL Lingle, AC Dueck, EA Perez - Mayo Clinic, Scottsdale AZ, Rochester MN, Jacksonville FL
HER2 Testing: How To Get High Concordance Rate between Immunohistochemistry and Fluorescence In Situ Hybridization
(240)
T Khoury, Y Zakharia, H Hwang, W Liu, S Edge, D Tan, C Morrison - Roswell Park Cancer Institute, Buffalo; Unity Hospital, Rochester; MD-Anderson Cancer Center, Houston
Uroplasminogen Receptor IHC Study in Triple Negative Breast Carcinoma
(282)
GM Oprea-Ilies, SE Pambuccian, R Gamez, A Young, C Cohen - Emory University, Atlanta, GA; Univeristy of Minnesota, Minneapolis, MN
The Concordance of Estrogen and Progesterone Receptor Status, and Her-2/Neu Expression in DCIS Coexistent with Micro-Invasive and Invasive Carcinoma
(134)
Q Ahmed, R Ali-Fehmi, W Sakr, Z Nahleh, Y Hussein, M Ibrahim, B Albashiti, K Hayek, I Khalifeh, S Bandyopadhyay - Wayne State University, Detroit, MI; Karmanos Cancer Institute, Detroit, MI; American University of Beirut, Beirut, Lebanon
ER and PR Discordances: Comparison of IHC by Local and Central Laboratory and RT-PCR by Central Laboratory in ECOG Breast Cancer Study 2197
(149)
FL Baehner, R Gray, B Childs, T Maddala, S Rowley, N Davidson, S Shak, LJ Goldstein, GW Sledge, JA Sparano, S Badve - University of California, San Francisco, San Francisco, CA; Eastern Cooperative Oncology Group, Indianapolis, IA; Sanofi Aventis, Bridgewater, NJ; GHI, Redwood City, CA
HER2 Diagnosis Program in Argentina with a Standardized and Reproducible Technique: Variation in Positive Rates throughout the Years
(195)
I Frahm, G Acosta Haab, S Sarancone, Grupo Her2, V Caceres - Sanatorio Mater Dei and Hospital Maria Curie, Buenos Aires, Argentina; Labotatorio Quantum, Rosario, Santa Fe, Argentina; Programa Nacional de Diagnostico de HER2, Argentina; Productos Roche, Tigre, Buenos Aires, Argentina
Automated Bright-Field Dual Color, Dual Hapten HER2 In Situ Hybridization Assay: An Alternative Method for Evaluation of HER2 Gene Amplification in Breast Cancer
(324)
LJ Tafe, J Teruya-Feldstein, A McElhinny, J Ranger-Moore, J Emch, C Schemp, V Barbashina - Memorial Sloan-Kettering Cancer Center, New York City, NY; Ventana Medical Systems, Inc., Tucson, AZ
Oligonucleotide Array Analysis of the HER2 Amplicon in Breast Cancers
(263)
I Lytvak, SR Gunn, I Yeh - University of Texas Health Science Center at San Antonio, San Antonio, TX
Comparative Assessment of Immunohistochemistry, Fluorescence In Situ Hybridization, and Silver-Enhanced In Situ Hybridization for Evaluation of HER2 Gene Status in Breast Carcinoma
(302)
Y Ryu, H Jeong, Y Kim, B Kim, H Kim, A Kim - Korea University Guro Hospital, Seoul, Korea
Determining HER-2/Neu Status on Needle Core Biopsies in the Neoadjuvant Setting: Does Florescence In-Situ Hybridization Remain the Gold Standard for 2+ Cases in These Smaller Samples?
(179)
T D'Alfonso, Y-F Liu, S Monni, PP Rosen, SJ Shin - Weill Cornell Medical College, NY, NY
Immunohistochemistry and In-Situ Hybridization for HER2 on a Single Slide Is Feasible and Allows Direct Comparison at the Individual Cell Level
(293)
ES Reisenbichler, A Andea, D Horton, O Hameed - University of Alabama, Birmingham, AL
Microarray Based Determination of ER, PR and HER2 Receptor Status Compared to Local IHC/FISH Assessment
(308)
G Seitz, J Palacios, JM Guinebretiere, E Lienen, P Roepman, L Stork-Sloots, R Bender, Y Tokunaga, T Watanabe - Institute of Pathology, Bamberg, Germany; Hospitales Universitarios Virgen del Rocio, Sevilla, Spain; Centre Rene Huguenin, Saint-Cloud, France; Agendia BV and Agendia Inc, Huntighton Beach, CA; Hamamatsu Oncology Center, Hamamatsu, Japan
Automated FISH Analysis for the HER2 Gene Status Assessment in Breast Cancer: A Validation Study Based on 306 Cases
(184)
G DeMaglio, G Falconieri, S Pizzolitto - General University Hospital, Udine, Italy
Amplification of the Oncogen HER2 by Immunohistoquemistry and FISH in Patients with Breast Cancer in Colombia. Analysis of 2879 Consecutive Cases Comparing Peripheral Laboratories and a Reference Institution
(142)
RE Andrade, A Plata, R Lopez - Hospital Universitario Fundacion Santa Fe de Bogota, Bogota, Colombia
Establishment of the Australian In Situ Hybridisation Program for the Assessment of HER2 Amplification in Breast Cancer: A Model for the Introduction of New Biomarkers into Clinical Practice
(193)
G Farshid, JE Armes, R Bell, M Cummings, S Fox, G Francis, M Haswell, A Morey, G McCue, W Raymond, P Robbins, M Bilous - SA Pathology, Adelaide, SA, Australia; Mater Health Services, Brisbane, QLD, Australia; Andrew Love Cancer Centre, Geelong, VIC, Australia; Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; Peter MacCallum Cancer Institute, Melbourne, VA, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia; Roche Australia, Sydney, NSW, Australia; St Vincent's Hospital, Sydney, NSW, Australia; Woolomin Consulting, Crookwell, NSW, Australia; Flinders Medical Centre, Adelaide, SA, Australia; Queen Elizabeth II Medical Centre, Perth, WA, Australia; Westmead Hospital, Sydney, NSW, Australia
Dual Color Chromogenic In Situ Hybridisation Seems To Detect a Different Subgroup of HER2/Neu Amplified Immunoscore 2+ Breast Carcinomas Compared to FISH
(250)
SF Lax, S Urdl, K Prein - General Hospital Graz West, Graz, Austria
Does Her2neu Expression Vary with Fixation Time?
(224)
JA Ibarra, LW Rogers - Memorial Care Breast Center at Orange Coast, Fountain Valley, CA; MemorialCare Breast Center at Long Beach, Long Beach, CA
Expression of Cyclin D1, MIB-1 (Ki-67) and Estrogen Receptor in Flat Epithelial Atypia
(169)
M Chivukula, G Carter, DJ Dabbs - Magee Women's Hospital of UPMC, Pittsburgh, PA
Effect of Formalin Fixation Time on Her 2 Expression by Immunohistochemical Technique
(186)
SM Dintzis, KH Allison - University of Washington, Seattle, WA
Impact of Decalcification on Receptor Status in Breast Cancer
(182)
F Darvishian, B Singh, S Krauter, L Chiriboga, J Melamed - NYU-Langone Medical Center, New York, NY
Estrogen Receptor and Progesterone Receptor Immunohistochemistry Results in Breast Carcinoma Using Varying Fixation Times in Different Fixatives
(260)
AC Lowe, N Moatamed, R Pucci, IP Shintaku, S Shapourifar-Tehrani, B Shackley, SK Apple - UCLA, Los Angeles, CA
Delay to Formalin Fixation Effect on Estrogen and Progesterone Receptors in Breast Cancer: A Study of Three Different Clones
(287)
J Qiu, S Kulkarni, R Chandrasekhar, M Rees, K Hyde, G Wilding, D Tan, T Khoury - Roswell Park Cancer Institute, Buffalo, NY; Leica Microsystems, Bannockburn, IL; Ventana, Tucson, AZ; MD-Anderson Cancer Center, Houston, TX
Concordance between Semi-Quantitative Immunohistochemical Evaluation and Oncotype Dx RT-PCR Derived ER, PR and HER-2 Status in Breast Cancer
(226)
R Jaffar, R Virk, D Kandil, S Lu, A Khan - U Mass Memorial Medical Center, Worcester, MA
The Oncotype DX Assay May Not Be Required for All Estrogen Receptor Positive Breast Cancers
(311)
JD Shiffer, B Obadia, S Apple, F Dadmanesh, E Wolin, P McAndrew, S Bose - Cedars Sinai Medical Center, Los Angeles; Kaiser Permanente, Woodland Hills; UCLA, Los Angeles, CA
Can Pathologic Features and Immunophenotype of ER+, Node Negative Breast Cancers Identify High and Low Risk OncotypeDX Subgroups?
(138)
KH Allison, SM Dintzis, PL Kandalaft, AM Gown, LC Goldstein - University of Washington, Seattle, WA; PhenoPath Laboratories, Seattle, WA; IMPRIS, Seattle, WA
Estrogen Receptor β Isoforms 1, 2 and 5 and Oncotype Recurrence Score
(196)
A Fung, A Adams, A Page, D Williams, C Cohen - Emory University Hospital, Atlanta, GA
The Relationship between Recurrence Score of 21-Gene Assay and Clinicopathological Factors of Breast Cancer
(344)
K Woolf, J Wang, DG Hicks, X Wang, LM Schiffhauer, K Skinner, P Tang - University of Rochester Medical Center, Rochester, NY; RTI Health Solutions, Research Triangle Park, NC
Estimation of Risk of Recurrence of Early Stage Estrogen Receptor Positive (ER+) Breast Carcinoma by Pathologists Compared to Oncotype Dx Recurrence Score - A Multi-Institutional Study
(130)
G Acs, NN Esposito, C Reynolds, TJ Lawton, I Bleiweiss, C Nagi, O Ioffe, O Hameed, D Dabbs, R Bhargava, MR Quddus, CJ Sung, M Gilcreast, A Sapino, G Cserni, J Kulka, J Jacquemier, P Regitnig, I Baas, P van Diest, C Quinn - Moffitt Cancer Center, Tampa, FL
Recurrence Score of 21-Gene Assay Is Correlated with a Panel of Immunopathological Factors of Breast Cancer
(322)
K Subik, A Delaney, J Wang, X Wang, LM Schiffhauer, M Shayne, A Huston, K Skinner, DG Hicks, P Tang - University of Rochester Medical Center, Rochester, NY; RTI Health Solutions, Research Triangle Park, NC
Comparative Analysis of Breast Prognostic Indicators by Immunohistochemistry and Oncotype DX
(180)
F Dadmanesh, B Obadia, S Apple, J Shiffer, P McAndrew, E Wolin, S Bose - Cedars Sinai Medical Center, Los Angeles, CA; UCLA Medical Center, Los Angeles, CA; Kaiser Permanente Medical Center, Woodland Hills, CA
Ki-67 Proliferative Index in Estrogen Receptor-Positive/HER2-Neu Negative Early Breast Cancer Predicts Oncotype DX Recurrence Score
(238)
C Kelly, RS Saad, S Nofech-Mozes, H Kahn, J Zubovits, J Wong, WM Hanna - Sunnybrook Health Sciences Center/University of Toronto, Toronto, ON, Canada
button next to any title to add to Itinerary Planner...
Add
